These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37589864)

  • 1. Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma.
    Gao Z; Wu S; Yang Y; Sun M; Tian X; Jin X
    Invest New Drugs; 2023 Oct; 41(5):719-726. PubMed ID: 37589864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.
    Wang Y; Yang X; Wang Y; Xue J; Zhang N; Yang X; Cong N; Zhang J; Zhu C; Zhang L; Hou X; Zhao H
    Cancer Immunol Immunother; 2023 Jul; 72(7):2197-2204. PubMed ID: 36856834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
    Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
    Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
    Ruff SM; Shannon AH; Pawlik TM
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computed tomography findings of hepatobiliary systems in patients with immune checkpoint inhibitor-induced liver injury.
    Masuoka S; Hiyama T; Kuno H; Sasaki T; Oda S; Miyasaka Y; Yamaguchi M; Kobayashi T
    Abdom Radiol (NY); 2023 Sep; 48(9):3012-3021. PubMed ID: 37294454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel pathologic marker, indoleamine 2,3-dioxygenase 1, for the cholangiopathy of immune checkpoint inhibitors-induced immune mediated hepatotoxicity as adverse events and the prediction of additional ursodeoxycholic acid treatment.
    Yoshimura K; Tamano Y; Nguyen Canh H; Zihan L; Le Thanh D; Sato Y; Terashima T; Shimoda S; Harada K
    Med Mol Morphol; 2023 Jun; 56(2):106-115. PubMed ID: 36599971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.
    Zhu C; Xue J; Wang Y; Wang S; Zhang N; Wang Y; Zhang L; Yang X; Long J; Yang X; Sang X; Zhao H
    Front Immunol; 2023; 14():1109292. PubMed ID: 36742297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer.
    Taghizadeh H; Prager GW
    Curr Cancer Drug Targets; 2022 Aug; 22(8):639-650. PubMed ID: 35168521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.
    Monge C; Pehrsson EC; Xie C; Duffy AG; Mabry D; Wood BJ; Kleiner DE; Steinberg SM; Figg WD; Redd B; Budhu A; Wang S; Tandon M; Ma L; Wei Wang X; Greten TF
    Oncologist; 2022 Mar; 27(3):e273-e285. PubMed ID: 35274717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.
    Mizuno K; Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Kawashima H; Inukai Y; Toyoda H; Yokota K; Hase T; Maeda O; Kiyoi H; Nagino M; Hibi H; Kodera Y; Fujimoto Y; Sone M; Gotoh M; Ando Y; Akiyama M; Hasegawa Y; Fujishiro M
    J Gastroenterol; 2020 Jun; 55(6):653-661. PubMed ID: 32124082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances of immunotherapy for biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
    [No Abstract]   [Full Text] [Related]  

  • 14. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.
    Nabeshima S; Yamasaki M; Matsumoto N; Takaki S; Nishi Y; Kawamoto K; Taniwaki M; Ohashi N; Hattori N
    Cancer Treat Res Commun; 2021; 26():100270. PubMed ID: 33338849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line chemotherapy or in combination with programmed cell death protein-1 antibody in patients with metastatic or recurrent biliary tract cancer.
    Zhao S; Guo XG; Zhang D; Zhou G; Song P; Yang J; Zhang Y; Li P; Hu Y; Wang P
    J Gastroenterol Hepatol; 2021 Dec; 36(12):3541-3547. PubMed ID: 34423859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.
    Chen X; Wang D; Liu J; Qiu J; Zhou J; Ying J; Shi Y; Wang Z; Lou H; Cui J; Zhang J; Liu Y; Zhao F; Pan L; Zhao J; Zhu D; Chen S; Li X; Li X; Zhu L; Shao Y; Shu Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.
    Pi B; Wang J; Tong Y; Yang Q; Lv F; Yu Y
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e858-e867. PubMed ID: 34482313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PD-1/PD-L1 in biliary tract cancer: role and available data.
    Mahmood RD; Graham K; Gleeson J; Hubner RA; Valle JW; McNamara MG
    Immunotherapy; 2023 May; 15(7):517-530. PubMed ID: 37009698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer.
    Liddell SS; Chakrabarti S; Wintheiser GA; Zemla TJ; Shi Q; Tella SH; Jin Z; Wookey VB; Hassan H; Tran NH; Borad MJ; Mahipal A
    JCO Precis Oncol; 2022 Jun; 6():e2200003. PubMed ID: 35772047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.